The UW School of Pharmacy has established a Drug Metabolism, Transport and Pharmacogenomic Research (DMTPR) program.
Pharmaceutical and biotech companies Merck, Eli Lilly, Bristol Myers Squibb, Roche, Amgen, Abbott and Pfizer have pledged unrestricted gifts totaling $2.05 million to enhance training and research activities within the School of Pharmacy. The new program will focus on understanding the genetic, molecular, biochemical and physiological factors affecting drug elimination processes, mechanisms of inter-individual variability in adverse drug responses, and evaluation of economic and clinical outcomes of therapeutic disease treatments.
DMTPR funds are currently being used to support recruitment of promising new research faculty, post-doctoral fellows and pre-doctoral students. Additional projects include undergraduate research, new instrumentation, and educational and research symposia.
“This investment,” said Dr. Ken Thummel, associate dean for research and new initiatives, “will help maintain the status of the School of Pharmacy as a Center of Excellence in drug disposition and outcomes research and ensure the training of exceptional scientists and future leaders for the pharmaceutical industry, federal and state regulatory agencies and academia.